RxDoctor Payments DataLook up a doctor →

John Calado, DO

Internal Medicine · Troy, MINPI 1972567113

Payments from drug & device makers

$197,645in general payments, 2019–2025

Across 699 payments — averaging $282.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$160K
  • Axsome Therapeutics, Inc.$30K
  • AbbVie$1K
  • AstraZeneca$974
  • Lilly USA, LLC$637
  • GSK$564
  • plus $4K from 37 others

What the payments were for

  • Consulting fees$2,0001%
  • Speaking & faculty fees$165,72584%
  • Travel & lodging$15,5728%
  • Food & beverage$14,2487%
  • Education$1000%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$197,645 in reported general payments places this provider in the 95th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$93,946
Medicare patients
104
Services billed
1,050

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab446$344,028
MounjaroTirzepatide145$151,600
Trelegy ElliptaFluticasone/Umeclidin/Vilanter90$85,671
EliquisApixaban59$75,503
AuvelityDextromethorphan Hbr/Bupropion48$61,280
VraylarCariprazine Hcl33$45,661
TrintellixVortioxetine Hydrobromide34$31,391
JardianceEmpagliflozin15$23,984
Emgality PenGalcanezumab-Gnlm34$22,546
MyrbetriqMirabegron27$22,522
OzempicSemaglutide18$21,871
Dexlansoprazole DrDexlansoprazole45$20,346
RybelsusSemaglutide13$17,494
Celecoxib304$13,849
BelbucaBuprenorphine Hcl13$12,137

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$637$151,600145 claims
GSKTrelegy Ellipta$564$85,67190 claims
PfizerEliquis$322$75,50359 claims
Axsome Therapeutics, Inc.Auvelity$29,501$61,28048 claims
AbbVieVraylar$1,264$45,66133 claims
Novo NordiskOzempic, Rybelsus$342$39,36531 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$177$36,04747 claims
Boehringer IngelheimJardiance$282$23,98415 claims
Astellas Pharma US IncMyrbetriq$236$22,52227 claims
Collegium Pharmaceutical, Inc.Belbuca$82$12,13713 claims
AstraZenecaBreztri Aerosphere$974$9,73216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Troy

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →